Boston Scientific Corp
BSX
Company Profile
Business description
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Contact
300 Boston Scientific Way
MarlboroughMA01752-1234
USAT: +1 508 683-4000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
53,000
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.50 | 12.40 | 0.14% |
| CAC 40 | 8,158.53 | 89.36 | 1.11% |
| DAX 40 | 24,872.13 | 311.15 | 1.27% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,202.18 | 64.09 | 0.63% |
| HKSE | 26,629.96 | 44.90 | 0.17% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,688.89 | 914.25 | 1.73% |
| NZX 50 Index | 13,556.87 | 17.06 | -0.13% |
| S&P 500 | 6,873.77 | 76.91 | 1.13% |
| S&P/ASX 200 | 8,848.70 | 12.80 | 0.14% |
| SSE Composite Index | 4,122.58 | 5.64 | 0.14% |